Centene Aktie News

SAN FRANCISCO, July 03, 2025 (GLOBE NEWSWIRE) -- On July 2, 2025, investors in Centene Corp. (NYSE: CNC) saw the price of their shares of this normally low-volatility stock crash 40%, after the company withdrew its guidance, blaming preliminary discussions and data generated by an independent actuary, Wakely.

Centene's 40% drop after pulling 2025 guidance is driven by rising medical costs and margin pressure, but the sell-off appears overdone. Historical patterns show that similar sell-offs in 2016 and 2020 were followed by recoveries as premiums were adjusted upward. Valuation is now highly attractive, with Price/Cash Flow below 8, making CNC stock a compelling buy despite sector volatility.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Centene Corporation (“Centene” or the “Company”) (NYSE: CNC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CENTENE CORPORATION (CNC), CLICK ...

CNBC's Jim Cramer offered his take on Centene and the broader health insurance space as its stock plummeted when management unexpectedly withdrew full-year guidance. "Given this news from Centene, I think the whole managed care industry is borderline un-investable right now," he said.

Major U.S. equities indexes finished Wednesday mixed as President Donald Trump announced that the U.S. has reached a trade deal with Vietnam.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Centene Corporation (“Centene” or the “Company”) (NYSE: CNC) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CENTENE CORPORATION (CNC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS ...

The health-insurance provider is reckoning with multiple threats to its business, potentially leaving it with fewer and less-healthy enrollees signed up to its health-insurance plans.

Centene's stock plunged  after slashing 2025 EPS guidance due to higher-than-expected morbidity and lower market growth in key states. The company's previous bullish guidance failed to materialize. Despite the sharp drop, Centene trades at historically low price-to-sales multiples and investment grade status, making valuation attractive for risk-tolerant investors.